Muses Labs announced today it has partnered with Metabolon, Inc., the global leader in metabolomics, to study and apply metabolomics in individuals with pre- and early-symptomatic cognitive decline and Alzheimer’s disease. The companies expect to bring new clinical trial services and updated care protocols to the market in 2016.
Metabolomics is the study of small molecules called metabolites and is a powerful phenotyping technology for precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle, and drug treatment.
“Muses Labs’ protocols utilize a patient’s genome, blood tests, medical history and lifestyle to direct care. Metabolomics adds additional significant insight into a patient’s biological status to improve identification of active pathologies and enable further refinement of patient care programs,” said Vik Chandra, CEO of Muses Labs. “Metabolomics has the potential to significantly expand the effectiveness of combination therapy protocols for Alzheimer’s and other complex diseases. Our collaboration with Metabolon has the power to advance precision medicine in this area.”
Muses Labs’ MEND™ Protocol is a data driven, technology enabled, personalized methodology to correctly identify and simultaneously treat the dozens of pathology drivers of age-related cognitive decline. It is designed to help patients who are beginning to have symptoms of age-related cognitive decline, those with a family history of dementia and patients with mild Alzheimer’s disease. The Protocol recommends optimal medical interventions personalized for each patient and has the potential to improve memory and cognitive function.
“We’re working together to expand the knowledge we can apply toward overcoming Alzheimer’s disease,” said John Ryals, PhD, CEO of Metabolon. “Our goal is to use our proprietary technology in conjunction with Muses Labs’ personalized Protocols to provide clinicians with a more accurate health assessment of patients experiencing cognitive decline as well as more actionable information. Metabolomics may help answer questions that surround complex, neurodegenerative diseases and refine personalized treatment.”
“While research into metabolomics and Alzheimer’s disease is in its early stages, we believe that by using this technology, the connections between metabolism and the underlying pathologies of Alzheimer’s disease will become better understood,” said Dr. Marwan Sabbagh, Research Professor of Neurology, University of Arizona College of Medicine, Chief Medical-Scientific Advisor, Muses Labs. “Metabolomics can guide the clinical care of Alzheimer’s disease today while laying the foundation for new interventions and protocols.”